SCHEMBL515981

SCHEMBL515981

CCC(O)Oc1cccc(C)c1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
ACHE P22303 1/20 0.48
ADRB2 P07550 1/20 0.45
ADRB1 P08588 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
ENPP3 O14638 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12751336 0.86 HSD17B1 (0.40) LMNAACHEADRB2ADRB1TDP1
SCHEMBL28029701 0.86 ENPP3 (0.48) LMNAACHEADRB2ADRB1TDP1
SCHEMBL10358918 0.84 LMNA (0.49) LMNAACHEADRB2ADRB1TDP1
SCHEMBL8527692 0.82 LMNA (0.47) LMNAACHEADRB2ADRB1TDP1
SCHEMBL27944867 0.81 ACHE (0.52) LMNAACHEADRB2ADRB1TDP1
SCHEMBL13791526 0.81 ACHE (0.52) LMNAACHETDP1L3MBTL1SMN1; SMN2
SCHEMBL13790939 0.79 ACHE (0.50) LMNAACHEADRB2ADRB1TDP1
SCHEMBL13791121 0.79 ACHE (0.50) LMNAACHEADRB2ADRB1TDP1
SCHEMBL3664622 0.79 TSHR (0.44) TDP1L3MBTL1SMN1; SMN2
SCHEMBL16978755 0.79 LMNA (0.55) LMNAACHEADRB2ADRB1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111465589-B Compound having fluorene skeleton and method for producing same 帝人株式会社 2024-01-05 CN disclosed
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same TEIJIN LIMITED (JP) 2022-05-24 US disclosed
EP-3747856-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME Teijin Limited (JP) 2020-12-09 EP disclosed
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME TEIJIN LIMITED (JP) 2020-11-12 US disclosed
CN-111465589-A Compound having fluorene skeleton and method for producing same 帝人株式会社 2020-07-28 CN disclosed
WO-2020085222-A1 CRYSTAL OF COMPOUND HAVING FLUORENE SKELETON AND METHOD FOR PRODUCING SAME 帝人株式会社 2020-04-30 WO disclosed
WO-2019151264-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME 帝人株式会社 2019-08-08 WO disclosed
US-8841491-B2 Method for producing fluorene derivative TAOKA CHEMICAL CO., LTD. (JP) 2014-09-23 US disclosed
EP-2420485-A1 METHOD FOR PRODUCING FLUORENE DERIVATIVE Taoka Chemical Co., Ltd. (JP) 2012-02-22 EP disclosed
US-20120029244-A1 METHOD FOR PRODUCING FLUORENE DERIVATIVE TAOKA CHEMICAL CO., LTD. (JP) 2012-02-02 US disclosed
EP-0391942-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1990-10-17 EP disclosed
US-4935540-A OXIDIZING ARYLOXYETHANOL IN PRESENCE OF PALLADIUM AND THALLIU M ON CARBON CATALYST, ACIDIFYING EASTMAN CHEMICAL COMPANY 1990-06-19 US disclosed
WO-1989003378-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (US) 1989-04-20 WO disclosed
US-4804777-A OXIDATION OF ARYLOXYETHANOL USING PALLADIUM, SILVER, CARBON CATALYST EASTMAN KODAK COMPANY (US) 1989-02-14 US disclosed
EP-0011793-B1 PROCESS FOR PREPARING ARYLOXYACETIC ACIDS BAYER AG (DE) 1981-09-02 EP disclosed
US-4238625-A ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1980-12-09 US disclosed
EP-0011793-A1 Process for preparing aryloxyacetic acids BAYER AG (DE) 1980-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME RFT1, AFF1, RER1 LMNA 1995/4885ACHE 4254/4885ADRB2 183/4885
US-20120029244-A1 METHOD FOR PRODUCING FLUORENE DERIVATIVE ADH1A, AFF2, AFF1 LMNA 1363/4885ACHE 3082/4885ADRB2 302/4885
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same RFT1, AFF1, RER1 LMNA 1995/4885ACHE 4254/4885ADRB2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.